Crescent Biopharma, Inc.
CBIO
$13.41
$0.322.45%
NASDAQ
| 09/30/2025 | |||||
|---|---|---|---|---|---|
| Net Income | -12.93% | ||||
| Total Depreciation and Amortization | 1,300.00% | ||||
| Total Amortization of Deferred Charges | -- | ||||
| Total Other Non-Cash Items | -72.44% | ||||
| Change in Net Operating Assets | 329.63% | ||||
| Cash from Operations | -6.93% | ||||
| Capital Expenditure | -318.57% | ||||
| Sale of Property, Plant, and Equipment | -- | ||||
| Cash Acquisitions | -- | ||||
| Divestitures | -- | ||||
| Other Investing Activities | -- | ||||
| Cash from Investing | -318.57% | ||||
| Total Debt Issued | -- | ||||
| Total Debt Repaid | -- | ||||
| Issuance of Common Stock | -- | ||||
| Repurchase of Common Stock | -608.47% | ||||
| Issuance of Preferred Stock | -- | ||||
| Repurchase of Preferred Stock | -- | ||||
| Total Dividends Paid | -- | ||||
| Other Financing Activities | -100.00% | ||||
| Cash from Financing | -100.85% | ||||
| Foreign Exchange rate Adjustments | -- | ||||
| Miscellaneous Cash Flow Adjustments | -- | ||||
| Net Change in Cash | -114.87% | ||||